Enrichment of mutations in chromatin regulators in people with Rett syndrome lacking mutations in MECP2

Academic Article

Abstract

  • © American College of Medical Genetics and Genomics. Purpose:Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by de novo mutations in MECP2 and sometimes in CDKL5 and FOXG1. However, some RTT patients lack mutations in these genes.Methods:Twenty-two RTT patients without apparent MECP2, CDKL5, and FOXG1 mutations were subjected to both whole-exome sequencing and single-nucleotide polymorphism array-based copy-number variant (CNV) analyses.Results:Three patients had MECP2 mutations initially missed by clinical testing. Of the remaining 19, 17 (89.5%) had 29 other likely pathogenic intragenic mutations and/or CNVs (10 patients had 2 or more). Interestingly, 13 patients had mutations in a gene/region previously reported in other neurodevelopmental disorders (NDDs), thereby providing a potential diagnostic yield of 68.4%. These mutations were significantly enriched in chromatin regulators (corrected P = 0.0068) and moderately enriched in postsynaptic cell membrane molecules (corrected P = 0.076), implicating glutamate receptor signaling.Conclusion:The genetic etiology of RTT without MECP2, CDKL5, and FOXG1 mutations is heterogeneous, overlaps with other NDDs, and complicated by a high mutation burden. Dysregulation of chromatin structure and abnormal excitatory synaptic signaling may form two common pathological bases of RTT.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Sajan SA; Jhangiani SN; Muzny DM; Gibbs RA; Lupski JR; Glaze DG; Kaufmann WE; Skinner SA; Annese F; Friez MJ
  • Start Page

  • 13
  • End Page

  • 19
  • Volume

  • 19
  • Issue

  • 1